Latest Regulatory News

Patronus Resources has clarified that its recent share price jump stems from a third-party research report rather than undisclosed company news, following an ASX inquiry. The company also confirmed the recent release of exploration results from its Western Australian gold projects.

Enlitic, Inc. has launched a A$10 million placement alongside an offer of 125 million unquoted options, aiming to fuel growth in its AI-driven healthcare technology business. The move underscores both funding ambitions and the complex risks tied to AI adoption and market dynamics.

Silk Logistics has announced a postponement of its shareholder Scheme Meeting due to an extended review by the Australian Competition and Consumer Commission (ACCC) of DP World Australia’s proposed acquisition.

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Renascor Resources has received provisional development authorisation from South Australia’s Minister for Planning to build a commercial-scale battery anode material plant, marking a pivotal step in its vertically integrated graphite project.

Juno Minerals has agreed to sell its Mount Mason DSO Hematite Project to Gold Valley Yilgarn for A$6 million plus a 2% royalty, unlocking cash and future income while focusing on its flagship Mount Ida Magnetite Project.

Cobre Limited has announced a fully underwritten loyalty options offer to raise approximately $1.18 million, offering eligible shareholders one new option for every three shares held at $0.008 each. The new options carry an exercise price of $0.066 and expire in November 2028.

WCM Global Growth Limited has renewed its on-market share buy-back program for 12 months, signaling ongoing confidence in its capital management strategy amid evolving market conditions.

Clarity Pharmaceuticals’ novel PET imaging agent Cu-SAR-Bombesin demonstrated safety and effectiveness in detecting prostate cancer recurrence missed by standard scans in its Phase II SABRE trial. The agent identified lesions in about one-third of patients with negative or equivocal standard imaging.

Invion Limited launches a Loyalty Option entitlement offer aimed at raising up to $16 million to support its advancing cancer clinical trials, including a promising anogenital cancer study with Peter MacCallum Cancer Centre.

EDU Holdings reports a remarkable 118% increase in total student enrolments at its Ikon Institute for Trimester 2, 2025, driven by strong demand and new course offerings amid a shifting regulatory landscape.

New World Resources has successfully completed a placement of 32 million shares at $0.02 each to its board and senior management, following shareholder approval. This move subtly reshapes the company’s capital structure ahead of its copper and base metals projects in the US.